$5.81 Billion is the total value of Avoro Capital Advisors LLC's 44 reported holdings in Q4 2020. The portfolio turnover from Q3 2020 to Q4 2020 was 43.5% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MRTX | Buy | MIRATI THERAPEUTICS INC | $996,067,000 | +38.1% | 4,535,000 | +4.4% | 17.15% | +67.4% |
| HZNP | Buy | HORIZON THERAPEUTICS PLC | $658,350,000 | +10.8% | 9,000,000 | +17.6% | 11.34% | +34.3% |
| UTHR | New | UNITED THERAPEUTICS CORP | $432,602,000 | – | 2,850,000 | +100.0% | 7.45% | – |
| IOVA | Sell | IOVANCE BIOTHERAPEUTICS INC | $348,000,000 | +10.9% | 7,500,000 | -21.4% | 5.99% | +34.4% |
| ARNA | Buy | ARENA PHARMACEUTICALS INC | $321,918,000 | +38.8% | 4,190,000 | +35.2% | 5.54% | +68.3% |
| ASND | ASCENDIS PHARMAsponsored adr | $300,204,000 | +8.1% | 1,800,000 | 0.0% | 5.17% | +31.0% | |
| SRPT | Buy | SAREPTA THERAPEUTICS INC | $298,358,000 | +26.8% | 1,750,000 | +4.5% | 5.14% | +53.7% |
| ARGX | ARGENX SEsponsored adr | $265,416,000 | +12.0% | 902,500 | 0.0% | 4.57% | +35.8% | |
| FOLD | Sell | AMICUS THERAPEUTICS INC | $207,810,000 | +35.6% | 9,000,000 | -17.1% | 3.58% | +64.4% |
| XLRN | Buy | ACCELERON PHARMA INC | $198,307,000 | +30.5% | 1,550,000 | +14.8% | 3.42% | +58.2% |
| MRSN | MERSANA THERAPEUTICS INC | $180,948,000 | +42.9% | 6,800,000 | 0.0% | 3.12% | +73.2% | |
| BMRN | Sell | BIOMARIN PHARMACEUTICAL INC | $144,689,000 | +8.7% | 1,650,000 | -5.7% | 2.49% | +31.7% |
| MDGL | Buy | MADRIGAL PHARMACEUTICALS INC | $136,183,000 | +28.9% | 1,225,000 | +37.6% | 2.34% | +56.2% |
| KURA | Buy | KURA ONCOLOGY INC | $130,640,000 | +75.1% | 4,000,000 | +64.3% | 2.25% | +112.3% |
| PMVP | Buy | PMV PHARMACEUTICALS INC | $130,536,000 | +126.7% | 2,350,267 | +27.0% | 2.25% | +174.8% |
| ACAD | New | ACADIA PHARMACEUTICALS INC | $104,247,000 | – | 1,950,000 | +100.0% | 1.80% | – |
| ADVM | ADVERUM BIOTECHNOLOGIES INC | $86,720,000 | +5.2% | 8,000,000 | 0.0% | 1.49% | +27.5% | |
| Buy | TRILLIUM THERAPEUTICS INC | $85,318,000 | +9.2% | 5,800,000 | +5.5% | 1.47% | +32.3% | |
| CNST | Sell | CONSTELLATION PHARMACEUTICALS INC | $84,960,000 | -1.9% | 2,950,000 | -31.0% | 1.46% | +18.8% |
| DCPH | Sell | DECIPHERA PHARMACEUTICALS INC | $74,191,000 | -20.5% | 1,300,000 | -28.6% | 1.28% | -3.7% |
| PRAX | New | PRAXIS PRECISION MEDICINES INC | $68,709,000 | – | 1,545,495 | +100.0% | 1.18% | – |
| CBAY | CYMABAY THERAPEUTICS INC | $59,122,000 | -20.7% | 10,300,000 | 0.0% | 1.02% | -3.9% | |
| ISEE | IVERIC BIO INC | $50,098,000 | +22.5% | 7,250,000 | 0.0% | 0.86% | +48.5% | |
| TVTX | New | TRAVERE THERAPEUTICS INC | $49,073,000 | – | 1,800,500 | +100.0% | 0.84% | – |
| RLMD | Buy | RELMADA THERAPEUTICS INC | $48,907,000 | -13.3% | 1,525,000 | +1.7% | 0.84% | +5.0% |
| XENE | XENON PHARMACEUTICALS INC | $43,064,000 | +38.9% | 2,800,000 | 0.0% | 0.74% | +68.6% | |
| New | MARINUS PHARMACEUTICALS INC | $39,432,000 | – | 3,232,142 | +100.0% | 0.68% | – | |
| OLMA | New | OLEMA PHARMACEUTICALS INC | $35,646,000 | – | 876,986 | +100.0% | 0.61% | – |
| AMRN | AMARIN CORP PLCsponsored adr | $29,340,000 | +16.2% | 6,000,000 | 0.0% | 0.50% | +40.7% | |
| AVDL | Buy | AVADEL PHARMACEUTICALS PLCsponsored adr | $29,158,000 | +37.7% | 4,365,000 | +3.9% | 0.50% | +66.8% |
| RLAY | RELAY THERAPEUTICS INC | $20,780,000 | -2.4% | 500,000 | 0.0% | 0.36% | +18.2% | |
| BDTX | Buy | BLACK DIAMOND THERAPEUTICS INC | $20,512,000 | +12.6% | 640,000 | +6.2% | 0.35% | +36.3% |
| ADAP | Sell | ADAPTIMMUNE THERAPEUTICS PLCsponsored adr | $19,135,000 | -78.2% | 3,550,000 | -67.7% | 0.33% | -73.5% |
| ITOS | ITEOS THERAPEUTICS INC | $15,557,000 | +37.1% | 460,000 | 0.0% | 0.27% | +66.5% | |
| RACA | THERAPEUTICS ACQUISITION CORP | $13,950,000 | -3.0% | 1,000,000 | 0.0% | 0.24% | +17.6% | |
| RNA | AVIDITY BIOSCIENCES INC | $13,908,000 | -9.3% | 545,000 | 0.0% | 0.24% | +10.1% | |
| FENC | FENNEC PHARMACEUTICALS INC | $12,442,000 | +22.9% | 1,670,000 | 0.0% | 0.21% | +48.6% | |
| GNCA | GENOCEA BIOSCIENCES INC | $12,304,000 | +5.7% | 5,084,184 | 0.0% | 0.21% | +28.5% | |
| MNKD | New | MANNKIND CORP | $10,955,000 | – | 3,500,000 | +100.0% | 0.19% | – |
| SNDX | New | SYNDAX PHARMACEUTICALS INC | $10,008,000 | – | 450,000 | +100.0% | 0.17% | – |
| BCTG | BCTG ACQUISITION CORP | $9,152,000 | +5.5% | 800,000 | 0.0% | 0.16% | +28.5% | |
| CUE | Sell | CUE BIOPHARMA INC | $5,661,000 | -79.9% | 452,500 | -75.8% | 0.10% | -75.8% |
| ATNX | Sell | ATHENEX INC | $4,120,000 | -89.6% | 372,500 | -88.6% | 0.07% | -87.3% |
| NKTR | New | NEKTAR THERAPEUTICScall | $26,000 | – | 100,000 | +100.0% | 0.00% | – |
| KYMR | Exit | KYMERA THERAPEUTICS INC | $0 | – | -49,400 | -100.0% | -0.02% | – |
| Exit | ALIMERA SCIENCES INC | $0 | – | -415,999 | -100.0% | -0.03% | – | |
| ZGNX | Exit | ZOGENIX INC | $0 | – | -875,000 | -100.0% | -0.22% | – |
| RAPT | Exit | RAPT THERAPEUTICS INC | $0 | – | -575,000 | -100.0% | -0.26% | – |
| RTRX | Exit | RETROPHIN INC | $0 | – | -1,325,000 | -100.0% | -0.35% | – |
| ALT | Exit | ALTIMMUNE INC | $0 | – | -2,000,000 | -100.0% | -0.38% | – |
| MRNS | Exit | MARINUS PHARMACEUTICALS INC | $0 | – | -3,000,000 | -100.0% | -0.55% | – |
| QURE | Exit | UNIQURE NV | $0 | – | -1,750,000 | -100.0% | -0.92% | – |
| KPTI | Exit | KARYOPHARM THERAPEUTICS INC | $0 | – | -6,000,000 | -100.0% | -1.24% | – |
| MYOK | Exit | MYOKARDIA INC | $0 | – | -1,885,000 | -100.0% | -3.65% | – |
| IMMU | Exit | IMMUNOMEDICS INC | $0 | – | -26,250,000 | -100.0% | -31.71% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-02-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| AMICUS THERAPEUTICS INC | 36 | Q3 2023 | 17.9% |
| MIRATI THERAPEUTICS INC. | 35 | Q3 2023 | 17.2% |
| BIOMARIN PHARMACEUTICAL INC | 31 | Q3 2023 | 8.0% |
| SAREPTA THERAPUTICS INC | 28 | Q3 2023 | 14.8% |
| ASCENDIS PHARMA | 28 | Q3 2023 | 9.1% |
| ARGENX SE | 26 | Q3 2023 | 9.5% |
| IOVANCE BIOTHERAPEUTICS INC | 26 | Q3 2023 | 9.1% |
| FENNEC PHARMACEUTICALS INC | 25 | Q3 2023 | 0.4% |
| MADRIGAL PHARMACEUTICALS INC | 22 | Q3 2023 | 7.2% |
| XENON PHARMACEUTICALS INC | 22 | Q3 2023 | 3.3% |
View Avoro Capital Advisors LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Adverum Biotechnologies, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| DICE Therapeutics, Inc. | February 14, 2023 | 2,525,555 | 5.3% |
| IOVANCE BIOTHERAPEUTICS, INC. | February 14, 2023 | 7,020,000 | 4.4% |
| IVERIC bio, Inc. | February 14, 2023 | 6,750,000 | 5.0% |
| Kura Oncology, Inc. | February 14, 2023 | 3,105,000 | 4.5% |
| Aadi Bioscience, Inc. | September 26, 2022 | 2,849,402 | 11.7% |
| ARENA PHARMACEUTICALS INC | February 11, 2022 | 1,235,000 | 2.0% |
| AVADEL PHARMACEUTICALS PLC | February 11, 2022 | 1,670,000 | 2.9% |
| FENNEC PHARMACEUTICALS INC. | February 11, 2022 | 1,200,000 | 4.6% |
| POINT Biopharma Global Inc.Sold out | February 11, 2022 | 0 | 0.0% |
View Avoro Capital Advisors LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G/A | 2024-04-23 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Avoro Capital Advisors LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.